EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exploratory pharmacokinetic-pharmacodynamic characterization and safety of standardized Andrographis paniculata aqueous extract capsules in patients with mild COVID-19

Phanit Songvut, Paruspak Payoong, Pilailuk Akkapaiboon Okada, Noppawan Rittapai, Sumitra Suntararuks, Jaratluck Akanimanee, Nuchanart Rangkadilok, Duangchit Panomvana, Porranee Puranajoti, Jutamaad Satayavivad

Frontiers in Pharmacology · 13.03.2026 · 17

DOI: 10.3389/fphar.2026.1781740 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 13.03.2026. Verfasst von Phanit Songvut und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Pharmacology, Chulabhorn Research Institute, Bangkok, Thailand. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Council of Thailand, Chulabhorn Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Andrographis paniculata has been used in the management of COVID-19-related conditions during the SARS-CoV-2 pandemic. However, human pharmacokinetic-pharmacodynamic (PK/PD) evidence to support a rationale for safe and evidence-based dosing of standardized extracts in clinical use remains limited. This exploratory study aimed to investigate the pharmacokinetics, preliminary PK/PD relationship, and short-term safety profile of standardized A. paniculata aqueous extract capsules in patients with mild COVID-19.

Methods

A single-center PK/PD clinical trial with two sequential phases (single-dose followed by multiple-dose) was conducted. Patients with mild COVID-19 received standardized A. paniculata aqueous extract capsules equivalent to 30 mg of andrographolide every 8 h (90 mg/day) for 5 consecutive days, alongside standard symptomatic treatment.

Results

Rapid absorption and elimination with limited systemic exposure supported repeated dosing to maintain exposure over the 5-day period. PK/PD analysis demonstrated a sigmoidal, saturable exposure-response relationship. The mean area under the concentration–time curve (AUC 0-4 h ) on day 5 approached the estimated EAUC 50 (half-maximal effective exposure) derived from the Emax model. A −2.96 log 10 reduction in viral load was observed; however, without a placebo control group, it is not possible to conclusively attribute this reduction to the investigational A. paniculata aqueous extract capsules. Adverse events were mild, with no hepatotoxicity or renal toxicity observed.

Conclusion

These findings provide preliminary evidence regarding the pharmacokinetics, dose-exposure characteristics, and short-term tolerability of standardized A. paniculata aqueous extract capsules, supporting further investigation in patients with mild COVID-19. Larger, placebo-controlled trials are warranted to establish causality and to evaluate clinical benefits.

Schlagwörter

Stichwörter der Autor:innen

Andrographis paniculataCOVID-19pharmacodynamicspharmacokineticssafety

Autor:innen und Institutionen

  • Laboratory of Pharmacology, Chulabhorn Research Institute, Bangkok, Thailand.
  • Center of Excellence on Environmental Health and Toxicology (EHT), OPS, MHESI, Bangkok, Thailand.
  • Department of Medicine, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, Thailand.
  • National Institute of Health, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand.
  • Translational Research Unit, Chulabhorn Research Institute, Bangkok, Thailand.

Förderung

  • National Research Council of Thailand
  • Chulabhorn Research Institute

Zitieren

APA

Songvut, P., Payoong, P., Okada, P. A., Rittapai, N., Suntararuks, S., Akanimanee, J., Rangkadilok, N., Panomvana, D., Puranajoti, P., & Satayavivad, J. (2026). Exploratory pharmacokinetic-pharmacodynamic characterization and safety of standardized Andrographis paniculata aqueous extract capsules in patients with mild COVID-19. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1781740

Vancouver

Songvut P, Payoong P, Okada PA, Rittapai N, Suntararuks S, Akanimanee J, et al. Exploratory pharmacokinetic-pharmacodynamic characterization and safety of standardized Andrographis paniculata aqueous extract capsules in patients with mild COVID-19. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1781740

BibTeX
@article{Songvut2026,
  author = {Songvut, Phanit and Payoong, Paruspak and Okada, Pilailuk Akkapaiboon and Rittapai, Noppawan and Suntararuks, Sumitra and Akanimanee, Jaratluck and Rangkadilok, Nuchanart and Panomvana, Duangchit and Puranajoti, Porranee and Satayavivad, Jutamaad},
  title = {Exploratory pharmacokinetic-pharmacodynamic characterization and safety of standardized Andrographis paniculata aqueous extract capsules in patients with mild COVID-19},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1781740}
}
Kostenlos starten →